Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Orbimed AdvisorsDirector | Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 05/27 | 05/29 | 101 sh | $44.49 | $4,493.49 | −0.0% |
Peter A. ThompsonDirector | Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 05/27 | 05/29 | 101 sh | $44.49 | $4,493.49 | −0.0% |
OrbiMed Capital GP VIIIDirector | Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 05/27 | 05/29 | 101 sh | $44.49 | $4,493.49 | −0.0% |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 05/07–05/11 | 05/11 | 292,952 sh3 trades | $45.62avg. | $13,364,064.5 | −9.9% | |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 05/07–05/11 | 05/11 | 292,952 sh3 trades | $45.62avg. | $13,364,064.5 | −9.9% | |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 05/07–05/11 | 05/11 | 292,952 sh3 trades | $45.62avg. | $13,364,064.5 | −9.9% | |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 04/17–04/18 | 04/21 | 55,345 sh2 trades | $44.67avg. | $2,472,342.92 | −1.8% | |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 04/17–04/18 | 04/21 | 55,345 sh2 trades | $44.67avg. | $2,472,342.92 | −1.8% | |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 04/17–04/18 | 04/21 | 55,345 sh2 trades | $44.67avg. | $2,472,342.92 | −1.8% | |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 04/14–04/16 | 04/16 | 510,583 sh3 trades | $44.94avg. | $22,945,043.5 | −14.5% | |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 04/14–04/16 | 04/16 | 510,583 sh3 trades | $44.94avg. | $22,945,043.5 | −14.5% | |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 04/14–04/16 | 04/16 | 510,583 sh3 trades | $44.94avg. | $22,945,043.5 | −14.5% | |
Jennifer FitzpatrickChief Legal Officer | Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 03/05 | 03/06 | 10,250 sh | $33.86 | $347,065 | −100.0% |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 02/02–02/03 | 02/04 | 30,953 sh2 trades | $44.58avg. | $1,379,865.84 | −0.9% | |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 02/02–02/03 | 02/04 | 30,953 sh2 trades | $44.58avg. | $1,379,865.84 | −0.9% | |
Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 02/02–02/03 | 02/04 | 30,953 sh2 trades | $44.58avg. | $1,379,865.84 | −0.9% | |
James G. Coulter10% Owner | Sionna TherapeuticsSION | Open-market sale | 01/22 | 01/26 | 250,000 sh | $40.00 | $10,000,000 | −3.7% |
Jon Winkelried10% Owner | Sionna TherapeuticsSION | Open-market sale | 01/22 | 01/26 | 250,000 sh | $40.00 | $10,000,000 | −3.7% |
TPG GP A10% Owner | Sionna TherapeuticsSION | Open-market sale | 01/22 | 01/26 | 250,000 sh | $40.00 | $10,000,000 | −3.7% |
Orbimed AdvisorsDirector | Sionna TherapeuticsSION | Open-market sale10b5-1 plan | 25/12/24 | 25/12/29 | 33,356 sh | $44.55 | $1,486,009.8 | −0.9% |